Scilex vs Verastem
Verastem reported revenue of $31 million in fiscal 2025, about the same as Scilex's $30 million in fiscal 2025. Scilex's revenue fell 46.5% in its latest year, and Verastem's grew 209.1%. Scilex had an operating margin of -1143.7%, against -550.3% at Verastem.
Side by side
| Scilex | Verastem | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $30M | $31M |
| Revenue growth | −46.5% | 209.1% |
| Revenue growth a year, last 5 years | 5.1% | −19.0% |
| Gross margin | — | — |
| Operating margin | −1,143.7% | −550.3% |
| Net margin | −1,236.4% | −677.6% |
| Free cash flow | $4M | — |
| Free cash flow margin | 12.2% | — |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 108,662.9% | 94.1% |
| Last close | $0.65 | $6.86 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $12.8 million | sold $680,195 |
| Piotroski F-score | 3 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ScilexVerastem
Operating margin
Percent of revenue
ScilexVerastem
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ScilexVerastem